静脉间充质干细胞治疗缺血性卒中的疗效与安全性
本研究为前瞻性、开放标签、随机对照试验,纳入严重大脑中动脉梗死90天内患者,按2:1分配接受自体预处理间充质干细胞(MSC)注射或标准治疗。主要结局3个月mRS评分无显著差异(p=0.732),但MSC组下肢运动功能(Motricity指数腿评分变化)显著改善(p=0.023),尤其在低预测恢复潜力患者中。无严重治疗相关不良事件。
要点
- 静脉自体预处理MSC在慢性严重卒中患者中可行且安全。
- MSC治疗未改善3个月mRS评分(p=0.732)。
- MSC组下肢运动功能显著改善(p=0.023),低恢复潜力者更明显。
核心结论
- 静脉应用自体预处理MSC在慢性严重卒中患者中可行且安全,但未改善3个月mRS评分,仅在详细功能分析中观察到下肢运动改善。
研究设计与样本
- 前瞻性、开放标签、随机对照试验,结局评估设盲,按2:1分配至MSC组或对照组。
- 最终意向性分析纳入MSC组39例、对照组15例,平均年龄68岁(范围28-83),卒中至随机平均20.2天(范围5-89)。
主要发现
- 3个月mRS评分移位两组无显著差异(p=0.732)。
- MSC组下肢运动功能较对照组显著改善(Motricity指数腿评分变化,p=0.023)。
- 低预测恢复潜力患者中下肢运动改善更明显。
- 无严重治疗相关不良事件。
关键数值与推荐
- 主要结局为3个月mRS评分,两组无显著差异(p=0.732)。
- 次要分析显示Motricity指数腿评分变化显著改善(p=0.023)。
- 证据等级:Class III证据表明自体MSC不改善慢性卒中患者90天结局。
临床怎么用
- 静脉自体预处理MSC治疗在慢性严重卒中患者中安全可行,但当前证据不支持其改善整体功能结局。
- 下肢运动功能改善提示MSC可能对特定患者亚组(如低恢复潜力者)有潜在益处,需进一步研究验证。
局限性
- 开放标签设计可能引入偏倚,尽管结局评估设盲。
- 样本量较小(MSC组39例,对照组15例),统计效能有限。
- 仅纳入严重大脑中动脉梗死患者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test whether autologous modified mesenchymal stem cells (MSCs) improve recovery in patients with chronic major stroke. METHODS: In this prospective, open-label, randomized controlled trial with blinded outcome evaluation, patients with severe middle cerebral artery territory infarct within 90 days of symptom onset were assigned, in a 2:1 ratio, to receive preconditioned autologous MSC injections (MSC group) or standard treatment alone (control group). The primary outcome was the score on the modified Rankin Scale (mRS) at 3 months. The secondary outcome was to further demonstrate motor recovery. RESULTS: A total of 39 and 15 patients were included in the MSC and control groups, respectively, for the final intention-to-treat analysis. Mean age of patients was 68 (range 28-83) years, and mean interval between stroke onset to randomization was 20.2 (range 5-89) days. Baseline characteristics were not different between groups. There was no significant difference between the groups in the mRS score shift at 3 months (p = 0.732). However, secondary analyses showed significant improvements in lower extremity motor function in the MSC group compared to the control group (change in the leg score of the Motricity Index, p = 0.023), which was notable among patients with low predicted recovery potential. There were no serious treatment-related adverse events. CONCLUSIONS: IV application of preconditioned, autologous MSCs with autologous serum was feasible and safe in patients with chronic major stroke. MSC treatment was not associated with improvements in the 3-month mRS score, but we did observe leg motor improvement in detailed functional analyses. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that autologous MSCs do not improve 90-day outcomes in patients with chronic stroke. CLINICALTRIALSGOV IDENTIFIER: NCT01716481.
引用
- Chung JW, Chang WH, Bang OY, et al. Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke. Neurology. 2021. PMID: 33472925. doi:10.1212/WNL.0000000000011440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。